Ravens Ursula, Cerbai Elisabetta
Department of Pharmacology and Toxicology, Medical Faculty, Dresden University of Technology, Dresden, Germany.
Europace. 2008 Oct;10(10):1133-7. doi: 10.1093/europace/eun193. Epub 2008 Jul 24.
Abnormal excitability of myocardial cells may give rise to ectopic beats and initiate re-entry around an anatomical or functional obstacle. As K(+) currents control the repolarization process of the cardiac action potential (AP), the K(+) channel function determines membrane potential and refractoriness of the myocardium. Both gain and loss of the K(+) channel function can lead to arrhythmia. The former because abbreviation of the active potential duration (APD) shortens refractoriness and wave length, and thereby facilitates re-entry and the latter because excessive prolongation of APD may lead to torsades de pointes (TdP) arrhythmia and sudden cardiac death. The pro-arrhythmic consequences of malfunctioning K(+) channels in ventricular and atrial tissue are discussed in the light of three pathophysiologically relevant aspects: genetic background, drug action, and disease-induced remodelling. In the ventricles, loss-of-function mutations in the genes encoding for K(+) channels and many drugs (mainly hERG channel blockers) are related to hereditary and acquired long-QT syndrome, respectively, that put individuals at high risk for developing TdP arrhythmias and life-threatening ventricular fibrillation. Similarly, down-regulation of K(+) channels in heart failure also increases the risk for sudden cardiac death. Mutations and polymorphisms in genes encoding for atrial K(+) channels can be associated with gain-of-function and shortened, or with loss-of-function and prolonged APs. The block of atrial K(+) channels becomes a particular therapeutic challenge when trying to ameliorate atrial fibrillation (AF). This arrhythmia has a strong tendency to cause electrical remodelling, which affects many K(+) channels. Atrial-selective drugs for the treatment of AF without affecting the ventricles could target structures such as I(Kur) or constitutively active I(K,ACh) channels.
心肌细胞的异常兴奋性可能引发异位搏动,并在解剖学或功能性障碍周围引发折返。由于钾离子电流控制心脏动作电位(AP)的复极化过程,钾离子通道功能决定了心肌的膜电位和不应期。钾离子通道功能的增强和丧失均可导致心律失常。前者是因为动作电位时程(APD)缩短会使不应期和波长缩短,从而促进折返;后者是因为APD过度延长可能导致尖端扭转型室性心动过速(TdP)心律失常和心源性猝死。本文将从三个与病理生理学相关的方面,即遗传背景、药物作用和疾病诱导的重塑,来探讨心室和心房组织中钾离子通道功能异常的促心律失常后果。在心室中,编码钾离子通道的基因突变和许多药物(主要是hERG通道阻滞剂)分别与遗传性和获得性长QT综合征相关,这使个体发生TdP心律失常和危及生命的室颤的风险很高。同样,心力衰竭时钾离子通道的下调也增加了心源性猝死的风险。编码心房钾离子通道的基因突变和多态性可能与功能增强和AP缩短,或与功能丧失和AP延长有关。在试图改善心房颤动(AF)时,阻断心房钾离子通道成为一项特殊的治疗挑战。这种心律失常有很强的导致电重塑的倾向,会影响许多钾离子通道。用于治疗AF而不影响心室的心房选择性药物可以靶向诸如I(Kur)或组成型活性I(K,ACh)通道等结构。